Therapy News and Research

RSS

CEL-SCI receives Polish government approval to commence Multikine Phase III clinical trial in head, neck cancer

CEL-SCI Corporation announced today that it has received approval to begin enrollment of patients in its Phase III clinical trial of Multikine® from the Polish Minister of Health. This approval marks a very important milestone, namely that all nine countries in the study have now given official government approval. Five of about 48 clinical centers for this global trial will be located in Poland.

5 May 2011

Researchers identify regulatory protein that can inhibit cancer metastasis

A protein capable of halting the spread of breast cancer cells could lead to a therapy for preventing or limiting the spread of the disease.

5 May 2011

New non-invasive blood test may detect early stage Alzheimer's

A new blood test that will diagnose Alzheimer's disease may soon hit the market, thanks to an innovative study from the Research Institute of the McGill University Health Centre.

4 May 2011

Durata receives positive EMA Scientific Advice on dalbavancin clinical development plan

Durata Therapeutics today announced the Company has received positive Scientific Advice from the European Medicines Agency on the pivotal clinical development plan for dalbavancin, Durata's long-acting, intravenous lipoglycopeptide for the treatment of acute bacterial skin and skin structure infections.

4 May 2011

Cardiac Dimensions initiates two CARILLON device trials in Functional Mitral Regurgitation

Cardiac Dimensions, Inc. announced today the initiation of two new clinical studies using the CARILLON Mitral Contour System, an investigational device for percutaneous treatment of Functional Mitral Regurgitation.

4 May 2011

Dehaier Medical first quarter revenue increases 12% to $2.95 million

Dehaier Medical Systems Ltd., an emerging leader in the development, assembly, marketing and sale of medical devices and homecare medical products in China, today announced its financial results for the first quarter ended March 31, 2011.

4 May 2011

Four medical centers enroll additional patients for NWBT's ongoing brain cancer trial

Northwest Biotherapeutics today announced that four medical centers across the country are actively recruiting and screening to enroll additional new patients in the Company's ongoing 240-patient randomized, double blind, placebo controlled clinical trial of DCVax immune therapy for Glioblastoma multiforme, the most lethal type of brain cancer.

4 May 2011

ChipDX identifies gene expression signature in early-stage breast tumors

ChipDX LLC, a New York-based molecular diagnostics and personalized medicine research company, has discovered a gene expression signature present in the cells of early-stage breast tumors that indicates the chance of the tumor recurring within 10 years.

4 May 2011

UW School of Pharmacy receives Dohmen donation to enhance students' education

Dohmen Company CEO Cynthia LaConte announced today that the Dohmen Company Foundation, the philanthropic arm of the 153-year-old healthcare services company, has donated $100,000 to the University of Wisconsin-Madison School of Pharmacy.

4 May 2011

New nano-vault delivery system can fight cancer

UCLA scientists have discovered a way to wake up the immune system to fight cancer by delivering an immune system-stimulating protein in a nanoscale container called a vault directly into lung cancer tumors, harnessing the body's natural defenses to fight disease growth.

4 May 2011

New research sheds light on origins of cryptococcal fungal infection

New research has shed light on the origins of a fungal infection which is one of the major causes of death from AIDS-related illnesses. The study, published today in the journal PLoS Pathogens, funded by the Wellcome Trust and the BBSRC, shows how the more virulent forms of Cryptococcus neoformans evolved and spread out of Africa and into Asia.

4 May 2011

FibroGen announces proof-of-principle for FG-4592 Phase 2 study in hemodialysis patients

FibroGen, Inc., today announced proof-of-principle for oral anemia therapy FG-4592, a hypoxia-inducible factor (HIF) prolyl hydroxylase inhibitor, in end-stage renal disease patients receiving hemodialysis.

4 May 2011

Ecstasy may cause long-term brain damage

Ecstasy - the illegal "rave" drug that produces feelings of euphoria and emotional warmth - has been in the news recently as a potential therapeutic. Clinical trials are testing Ecstasy in the treatment of post-traumatic stress disorder.

4 May 2011

AHF cautions against fast track FDA-approval for expanded use of Gilead’s Truvada

During its quarterly meeting over the weekend, The Board of Directors of the AIDS Healthcare Foundation (AHF) adopted a resolution cautioning Gilead Sciences against seeking fast track FDA-approval for the expanded use of its best selling AIDS treatment, Truvada, as a possible form of pre-exposure prophylaxis (PrEP) to prevent the transmission of HIV.

4 May 2011

Asthma prevalence jump alarms health experts

According to the Centers for Disease Control and Prevention in a report released this Tuesday, Americans are suffering from asthma in record numbers. Nearly one in 10 children and almost one in 12 Americans of all ages now has asthma, government researchers said. Tuesday was World Asthma Day.

4 May 2011

Cancers use body's own defences to resist drugs

CANCER RESEARCH UK scientists have discovered that tumours are able to recruit part of the body's defence system to protect them from the effect of a drug designed to block the supply of blood to the tumour.

4 May 2011

iOWH, Center for World Health and Medicine partner to combat childhood diarrhea

The Center for World Health and Medicine at Saint Louis University and the Institute for OneWorld Health have established a joint research agreement to develop new drugs to combat diarrhea, which is the second leading cause of death worldwide in children under age 5.

4 May 2011